Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Breast Neoplasms 12Pancreatic Neoplasms 6Neoplasms 6Prostatic Neoplasms 5Ovarian Neoplasms 5Leukemia, Myeloid, Acute 5Head and Neck Neoplasms 5Urinary Bladder Neoplasms 4Multiple Myeloma 4Lung Neoplasms 4Leukemia 4Colorectal Neoplasms 4Recurrence 3Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Radiodermatitis 2Neoplasms by Site 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Glioma 2Glioblastoma 2Gastrointestinal Neoplasms 2Communication 2Carcinoma, Transitional Cell 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1

Interventions

Dexamethasone 32Cyclophosphamide 30fludarabine phosphate 25Melphalan 25Busulfan 25Bortezomib 21Tacrolimus 20Lenalidomide 19Peripheral Blood Stem Cell Transplantation 18Mycophenolic Acid 17Whole-Body Irradiation 16Antilymphocyte Serum 16fludarabine 14Calcium Dobesilate 13Thalidomide 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Methotrexate 10pomalidomide 9Cyclosporine 8Radiotherapy 6Etoposide 6Cord Blood Stem Cell Transplantation 6Surveys and Questionnaires 5Stem Cell Transplantation 5Rituximab 5Methylprednisolone 5sargramostim 4carfilzomib 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Neoplasms, Plasma Cell × Standard of Care × Clear all
NCT06504524 2025-06-27

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Pfizer

Completed
633 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05932290 2024-10-29

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
514 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05565391 2024-05-21

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

Pfizer

Completed
508 enrolled 16 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡